Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy vs Chemotherapy in Advanced Endometrial Cancer
NCT00942357Phase 3Unknown
- Sponsor
- GOG Foundation
- Start
- Jun 2009
- Primary completion
- Feb 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in endometrial carcinoma (2 arms), sponsored by GOG Foundation. Primary endpoint: Recurrence-Free Survival at 5 years. Status: unknown.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00942357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942357.